标题
Recent advances in systemic therapy for hepatocellular carcinoma
作者
关键词
-
出版物
Biomarker Research
Volume 10, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-01-10
DOI
10.1186/s40364-021-00350-4
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study.
- (2021) Philippe Merle et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study.
- (2021) Jean-Luc Van Laethem et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040.
- (2021) Anthony B. El-Khoueiry et al. JOURNAL OF CLINICAL ONCOLOGY
- FGFR-TKI resistance in cancer: current status and perspectives
- (2021) Sitong Yue et al. Journal of Hematology & Oncology
- Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate
- (2021) Fan-En Kong et al. Science Translational Medicine
- Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
- (2021) Shukui Qin et al. Lancet Gastroenterology & Hepatology
- Comparison of Efficacy of Systemic Therapies in Advanced Hepatocellular Carcinoma: Updated Systematic Review and Frequentist Network Meta-Analysis of Randomized Controlled Trials
- (2021) Robin Park et al. Journal of Hepatocellular Carcinoma
- Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
- (2021) A. Bardia et al. ANNALS OF ONCOLOGY
- Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
- (2021) Thomas Decaens et al. BRITISH JOURNAL OF CANCER
- A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma
- (2020) Christos Fountzilas et al. BRITISH JOURNAL OF CANCER
- Downregulation of CLDN6 inhibits cell proliferation, migration, and invasion via regulating EGFR/AKT/mTOR signalling pathway in hepatocellular carcinoma
- (2020) Lingyuan Huang et al. CELL BIOCHEMISTRY AND FUNCTION
- Analysis of OX40 agonist antibody (PF-04518600) in patients with hepatocellular carcinoma.
- (2020) Anthony B. El-Khoueiry et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular therapies for HCC: Looking outside the box
- (2020) Sandrine Faivre et al. JOURNAL OF HEPATOLOGY
- Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
- (2020) Shukui Qin et al. LANCET ONCOLOGY
- Glypican-3–Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma
- (2020) Sai Arun Batra et al. Cancer Immunology Research
- Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase 1 Trials
- (2020) Donghua Shi et al. CLINICAL CANCER RESEARCH
- Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).
- (2020) Robin Kate Kelley et al. JOURNAL OF CLINICAL ONCOLOGY
- T cell-engaging therapies — BiTEs and beyond
- (2020) Maria-Elisabeth Goebeler et al. Nature Reviews Clinical Oncology
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma
- (2020) Michele Dal Bo et al. DRUG RESISTANCE UPDATES
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
- (2020) Michael S Lee et al. LANCET ONCOLOGY
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma
- (2020) Matthias Pinter et al. JAMA Oncology
- Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma
- (2020) Mohamad Bassam Sonbol et al. JAMA Oncology
- Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
- (2020) John D. Gordan et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- A Case of Isolated Cecal Necrosis Preoperatively Diagnosed with Perforation of Cecum
- (2019) Atsushi Kohga et al. Medicina-Lithuania
- Antibody-Drug Conjugate-Based Therapeutics: State of the Science
- (2019) Michael J Birrer et al. JNCI-Journal of the National Cancer Institute
- GITR ligation enhances functionality of tumor‐infiltrating T cells in hepatocellular carcinoma
- (2019) Adriaan A. Beek et al. INTERNATIONAL JOURNAL OF CANCER
- An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer
- (2019) Steven Feins et al. AMERICAN JOURNAL OF HEMATOLOGY
- First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).
- (2019) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma
- (2019) Xiuqi Wu et al. MOLECULAR THERAPY
- A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
- (2019) R.K. Kelley et al. Clinical and Translational Gastroenterology
- New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma
- (2019) Mossenta et al. Cancers
- Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
- (2019) Shuyan Dai et al. Cells
- Antibody–drug conjugates for cancer
- (2019) Cindy H Chau et al. LANCET
- Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities
- (2019) Chen Lu et al. Molecular Cancer
- First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma
- (2019) Richard D Kim et al. Cancer Discovery
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- Antibody-Drug Conjugates: A Comprehensive Review
- (2019) Puregmaa Khongorzul et al. MOLECULAR CANCER RESEARCH
- Immunotherapy for hepatocellular carcinoma
- (2019) Yin Zongyi et al. CANCER LETTERS
- Hepatocellular carcinoma in the era of immunotherapy
- (2018) Hao-Wen Sim et al. CURRENT PROBLEMS IN CANCER
- Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma
- (2018) Mohamed Bouattour et al. HEPATOLOGY
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Next generation of immune checkpoint therapy in cancer: new developments and challenges
- (2018) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
- (2018) Richard S. Finn et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Hepatocellular carcinoma
- (2018) Alejandro Forner et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
- (2018) Lorenza Rimassa et al. LANCET ONCOLOGY
- Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes
- (2018) Jian Wang et al. Nanomedicine-Nanotechnology Biology and Medicine
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- Targeting VEGF/VEGFR to Modulate Antitumor Immunity
- (2018) Ju Yang et al. Frontiers in Immunology
- A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors
- (2018) Maxim Kebenko et al. OncoImmunology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Combinations of Bevacizumab With Cancer Immunotherapy
- (2018) Daniel S. Chen et al. CANCER JOURNAL
- Structures of β-klotho reveal a ‘zip code’-like mechanism for endocrine FGF signalling
- (2018) Sangwon Lee et al. NATURE
- Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
- (2018) Jianming Xu et al. CLINICAL CANCER RESEARCH
- Glypican-3 Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma
- (2018) Ying Fu et al. HEPATOLOGY
- Tim-3 expression and its role in hepatocellular carcinoma
- (2018) Feifei Liu et al. Journal of Hematology & Oncology
- Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects
- (2018) Xiaoyun Lu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas
- (2017) Guoying Zhou et al. GASTROENTEROLOGY
- Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo
- (2017) Zhaoxiong Ma et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
- (2017) Matthew D Hellmann et al. LANCET ONCOLOGY
- Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma
- (2017) Jian-Yang Ao et al. MOLECULAR CANCER THERAPEUTICS
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials
- (2017) Masatoshi Kudo ONCOLOGY
- An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
- (2017) Takahiro Ishiguro et al. Science Translational Medicine
- Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor
- (2017) Jonathan M. Yingling et al. Oncotarget
- A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies
- (2017) Alexander K. Tsai et al. Cancer Immunology Research
- Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply
- (2017) Ken Liu et al. Clinical and Translational Gastroenterology
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Novel TGF-β inhibitors ready for prime time in onco-immunology
- (2016) Armand de Gramont et al. OncoImmunology
- Hepatocellular carcinoma
- (2016) Josep M. Llovet et al. Nature Reviews Disease Primers
- Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma
- (2015) Jiang Chen et al. CANCER LETTERS
- Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib
- (2015) Massimo Iavarone et al. HEPATOLOGY
- SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
- (2015) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Targeting the TGFβ pathway for cancer therapy
- (2015) Cindy Neuzillet et al. PHARMACOLOGY & THERAPEUTICS
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib
- (2015) AG Duffy et al. United European Gastroenterology Journal
- Issue Information
- (2015) JOURNAL OF CLINICAL PHARMACOLOGY
- Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma
- (2014) H. Gao et al. CLINICAL CANCER RESEARCH
- Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET
- (2014) Q. Xiang et al. CLINICAL CANCER RESEARCH
- Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions
- (2014) Tai Hato et al. HEPATOLOGY
- Tumor-Associated Macrophages: From Mechanisms to Therapy
- (2014) Roy Noy et al. IMMUNITY
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- (2014) Andrew X. Zhu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine
- (2014) Anna R Kwilas et al. Journal of Translational Medicine
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Tumor-associated antigen specific CD8+T cells in hepatocellular carcinoma – a promising target for immunotherapy
- (2014) Nathalie Schmidt et al. OncoImmunology
- An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression
- (2013) Pengfei Zhang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer
- (2013) A. X. Zhu et al. CLINICAL CANCER RESEARCH
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- A Human Anti-c-Met Fab Fragment Conjugated with Doxorubicin as Targeted Chemotherapy for Hepatocellular Carcinoma
- (2013) Ximin Chen et al. PLoS One
- Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist
- (2012) A. Fasolo et al. ANNALS OF ONCOLOGY
- TGF-β signalling and its role in cancer progression and metastasis
- (2012) Yvette Drabsch et al. CANCER AND METASTASIS REVIEWS
- Efficacy, Safety, and Biomarkers of Single-Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2012) V. Boige et al. ONCOLOGIST
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy
- (2011) Massimo Iavarone et al. HEPATOLOGY
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Tumor angiogenesis: molecular pathways and therapeutic targets
- (2011) Sara M Weis et al. NATURE MEDICINE
- Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects
- (2010) W. Zhang et al. CLINICAL CANCER RESEARCH
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model
- (2010) Richard S. Finn et al. LIVER INTERNATIONAL
- High Expression of Macrophage Colony-Stimulating Factor-1 Receptor in Peritumoral Liver Tissue Is Associated with Poor Outcome in Hepatocellular Carcinoma After Curative Resection
- (2010) J.-B. Jia et al. ONCOLOGIST
- Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes
- (2009) C Alfaro et al. BRITISH JOURNAL OF CANCER
- FGF19-induced Hepatocyte Proliferation Is Mediated through FGFR4 Activation
- (2009) Xinle Wu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Tie2 in Tumor Endothelial Signaling and Survival: Implications for Antiangiogenic Therapy
- (2009) J. H. Tsai et al. MOLECULAR CANCER RESEARCH
- Endosialin (Tem1) Is a Marker of Tumor-Associated Myofibroblasts and Tumor Vessel-Associated Mural Cells
- (2008) Sven Christian et al. AMERICAN JOURNAL OF PATHOLOGY
- Endoglin (CD105) Expression Is Regulated by the Liver X Receptor Alpha (NR1H3) in Human Trophoblast Cell Line JAR1
- (2008) Joëlle Henry-Berger et al. BIOLOGY OF REPRODUCTION
- EpCAM and -Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma
- (2008) T. Yamashita et al. CANCER RESEARCH
- Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase
- (2008) J. Matsui et al. CLINICAL CANCER RESEARCH
- Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2008) Abby B. Siegel et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation